National Cancer Institute Selects Zecotek’s Tunable Green Fiber Laser for Applications in Flow Cytometry
Singapore, December 15, 2009 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in flow cytometry. The TGFL is the world’s first tunable fiber laser emitting in the visible wavelength range. This latest order follows the purchase by the National Cancer Institute of Zecotek’s Fixed Wavelength Green Fiber Laser (FGFL), for cytometric research. Dr. William Telford, Head of the Flow Cytometry Core Laboratory at the National Cancer Institute/NIH is leading the experimental work to be conducted with this laser.
“The wavelength range that Zecotek’s Tunable Green Fiber Laser provides is ideal for our research which is aimed at discovering new fluorescent probes for application in immunology, hematology, organ transplantation and biomedical research,” said Dr. Telford.
“We are very gratified the National Cancer Institute has selected our Tunable Green Fiber Laser for an area of research that directly contributes to advancements in bio-instrumentation,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. “Dr. Telford’s research is closely followed by industry and his results have contributed to the strong interest from bio-instrumentation OEMs in our FGFL and TGFL for flow cytometry and other systems which, we anticipate, will contribute to strong sales growth in early 2010.”
Under an extension of the joint manufacturing agreement with Fujikura, the FGFL and TGFL series will carry the Zecotek label in North America, with manufacturing and manufacturer’s warranty remaining with Fujikura of Japan.
About Zecotek Lasers
Zecotek’s fiber laser portfolio comprises of blue and green wavelength emitting lasers, Raman fiber lasers, and femtosecond lasers. The Company’s laser products are aimed at OEM manufacturers of medical and industrial systems who are looking for the higher power at specific wavelengths available from fiber sources. The laser products are also attractive for use in fundamental and applied research.
Zecotek’s blue-green fiber lasers have been specifically developed as higher performance, lower cost replacements argon ion and solid-state laser wavelengths in applications including:
- Bio-instrumentation: DNA sequencing, flow Cytometry, scanning laser microscopy;
- Medicine: ophthalmology, dermatology, urology;
- Printing and imaging, inspection and measurement;
- Laser writing and lithography: laser writing, lithography and sintering;
- Fundamental research: spectroscopy, fluorescence analysis.
Features of Zecotek’s blue-green fiber lasers include:
- Broad range of operating wavelengths: 458, 488, 515, 529, 531 (Ar/Kr ion laser replacement), 532 (DPSS replacement), 540, 550, 560 (additional) and many others in the range 450-570 nm; Specification sheets available for 540 nm and 550 nm;
- Tuneability (greater than10 nm);
- Multi-wavelength and narrow-band options.
Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) is a photonics technology company developing high-performance crystals, photo detectors, lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Zecotek Photonics Inc.
CHF Investor Relations
(416) 868-1079 x237
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.